Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Fresh from the Pipeline
  • Published:

Enfuvirtide

Nature Reviews Drug Discovery volume 2, pages 345–346 (2003)Cite this article

Abstract

Enfuvirtide (Fuzeon; Trimeris/Roche), the first in a new class of anti-HIV drugs that inhibit the entry of the virus into cells, was approved by the US FDA in March 2003 for the treatment of HIV-1 infection in treatment-experienced patients. Is it likely to become a blockbuster?

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Mode of action of enfuvirtide.
Figure 2: Market for anti-HIV drugs.

References

  1. Lalezari, J. P. et al. Enfuvirtide, an HIV-1 fusion inhibitor for drug-resistant HIV infection in North and South America. N. Engl. J. Med. (2003) Mar 13 (doi: 10.1056/NEJMoa035026)

  2. De Clercq, E. Strategies in the design of antiviral drugs. Nature Rev. Drug Discov. 1, 13–25 (2002).

    Article  CAS  Google Scholar 

  3. Wild, C. T. et al. Peptides corresponding to a predictive α-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc. Natl Acad. Sci. USA 91, 9770–9774 (1994).

    Article  CAS  Google Scholar 

  4. Kilby, J. M. et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nature Med. 4, 1302–1307 (1998).

    Article  CAS  Google Scholar 

  5. FDA Drug Approvals List [online] (cited 28 March 2003) <http://www.fda.gov/cder/foi/label/2003/021481lbl.pdf> (2003).

Download references

Author information

Authors and Affiliations

  1. Decision Resources Inc., 260 Charles Street, Waltham, 02453, Massachusetts, USA

    Jason LaBonte & John Lebbos

  2. Nature Reviews Drug Discovery,

    Peter Kirkpatrick

Authors
  1. Jason LaBonte
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John Lebbos
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter Kirkpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jason LaBonte.

Rights and permissions

Reprints and permissions

About this article

Cite this article

LaBonte, J., Lebbos, J. & Kirkpatrick, P. Enfuvirtide. Nat Rev Drug Discov 2, 345–346 (2003). https://doi.org/10.1038/nrd1091

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd1091

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing